3 results
During the course of the study 2 randomisation questions will be adressed. Both questions concern patients in the high risk group.Randomisation question 1: Will the addition of Doxorubicin to the first 4 standard IVA chemotherapy courses lead to a…
The purpose of this Safety Lead In study is to explore if encorafenib and cetuximab in combination with a chemotherapy regimen (either mFOLFOX6 or FOLFIRI) are safe and have beneficial effects on you and your colorectal cancer. This is a small…
Primary Objective• To compare the annualised total bleeding rate of individually tailored prophylaxis with the historical bleeding rate observed in patients having received on-demand treatment with Human-cl rhFVIII from study GENA-01Secondary…